Citigroup Inc. started coverage on shares of Eleven Biotherapeutics (NASDAQ:EBIO) in a research report released on Monday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $35.00 price objective on the stock. Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares after opening at $16.09 moved to $16.52 on last trade day and at the end of the day closed at $16.23.Company price to sales ratio in past twelve months was calculated as 327.44 and price to cash ratio as 67.17.Eleven Biotherapeutics Inc (NASDAQ:EBIO) showed a negative weekly performance of -2.29%.
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced financial results for the quarter and year ended December 31, 2013. Celladon Corp (NASDAQ:CLDN) shares advanced 5.86% in last trading session and ended the day on $11.92. CLDN return on equity ratio is recorded as 83.40% and its return on assets is -105.30%.
Zacks initiated coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research report issued on Wednesday, AmericanBankingNews.com reports. The firm set a “hold” rating on the stock. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares moved up 7.00% in last trading session and was closed at $48.89, while trading in range of $44.62-$48.96. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) year to date performance is 15.72%.
Leerink Swann assumed coverage on shares of Eleven Biotherapeutics (NASDAQ:EBIO) in a research note issued to investors on Monday,TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. Eleven Biotherapeutics Inc (NASDAQ:EBIO) weekly performance is -2.29%. On last trading day company shares ended up $16.23. Eleven Biotherapeutics Inc (NASDAQ:EBIO) distance from 50-day simple moving average is 8.63%. Analysts mean target price for the company is $29.67.